DR. MARTENS PLC (3U2.F)

0.92EUR +1.44% (+0.01)

Over 1Y: -8.1%

2026-08-25

0.8 1

Aug Oct Dec Feb Apr Jun Aug

Figures as at 2026-03-29, reported in GBP. The newest fact in the filings is dated 2026-03-30, 149 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

8.0

SBC / sales 0.68%

OE margin 16.8%

Resilience

Can the balance sheet absorb a bad year?

5.1

Current ratio 2.6×

ND/EBITDA —

Growth

Is the business getting bigger, and is it getting more profitable?

1.0

Sales/sh Y/Y -2.9%

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.

The ratios

The figures themselves rather than their scores — what somebody looking up 3U2.F on one particular measure came for.

Ratio	Value
current ratio	2.61
current ratio reported	2.61
fcf margin	17.45
owner earnings margin	16.77
revenue growth	-2.88
revenue growth per share	-2.88
sbc pct revenue	0.68

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

Figure	Value	XBRL tag	As at
capex	9,200,000	`PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities`	2026-03-29
cash	180,300,000	`CashAndCashEquivalents`	2026-03-30
current assets	417,100,000	`CurrentAssets`	2026-03-30
current liabilities	159,900,000	`CurrentLiabilities`	2026-03-30
equity	361,500,000	`Equity`	2026-03-30
interest expense	28,000,000	`FinanceCosts`	2026-03-29
ocf	142,700,000	`CashFlowsFromUsedInOperatingActivities`	2026-03-29
revenue	764,900,000	`Revenue`	2026-03-29
sbc	5,200,000	`AdjustmentsForSharebasedPayments`	2026-03-29

What to be careful about

revenue is annual, not TTM
no operating income found in XBRL
no market cap; set `market_cap` in overrides.yaml
reports in GBP and quotes in EUR, so the share price is converted at 1 EUR = 0.8556 GBP as at 2026-08-26. Only the price is converted: every figure from the filing is as reported, and only the multiples built on market capitalisation carry the rate — but no share count is available, so there is still no market capitalisation
no usable diluted share count, so growth is measured on total revenue rather than per share; a company issuing shares to fund that growth reads better than it is
no forward EPS estimate; growth rests on filings only. Analyst consensus is not published in XBRL, so it has to be fetched from a data provider or set by hand in overrides.yaml as `eps_growth_2y`

See it scored yourself

The dashboard puts 3U2.F beside other companies and lets you change what counts: the weight of each dimension, the value that earns a ten, and which of the 61 measures are included at all.